Sign up
Pharma Capital

Aequus Pharmaceuticals establishes advisory board in ophthalmology

They are Dr Ike Ahmed who will become chairman and Dr Rosa Braga-Mele, who comes from the University of Toronto.
The company has established an advisory board

Aequus Pharmaceuticals Inc (CVE:AQS) told investors it had established a strategic advisory board in ophthalmology and appointed its first two members.

They are Dr Ike Ahmed of the Prism Eye Institute, who will become chairman and Dr Rosa Braga-Mele, who comes from the University of Toronto.

This board will help Aequus in determining whether a product can improve patient outcomes, integrate into a clinician's workflow, and navigate the Canadian reimbursement and commercial landscape.

"The formation of our advisory board is another step in our continued commitment to the ophthalmic space in Canada," said Doug Janzen, chairman and CEO of Aequus Pharmaceuticals.

Dr Ahmed has become world renowned for his skills and ground-breaking work in the diagnosis and surgical treatment of highly complex eye diseases including glaucoma and surgical complications

Dr Rosa Braga-Mele is a cataract specialist and educator who speaks frequently at both the national and international level on advanced surgical techniques, innovations in phacoemulsification surgery, complicated cataract cases, and IOL development.


Register here to be notified of future AQS Company articles
View full AQS profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.